PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.84+0.11 (+6.36%)
Close on Oct 19, 2026
- Market cap
- $571.61M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $136.05M | $136.18M | $135.76M | $130.89M | $133.59M | $132.25M | $136.15M | $156.05M | $172.32M | $184.23M | $183.87M | $152.64M | 85.4% | +1.8% |
| Consumable revenue | $84.83M | $83.66M | $81.94M | $79.12M | $76.35M | $74.49M | $70.37M | $70.43M | $68.79M | $65.45M | $63.42M | $61.22M | 53.3% | +11.1% |
| Instrument revenue | $51.21M | $52.52M | $53.82M | $51.77M | $57.24M | $57.77M | $65.78M | $85.63M | $103.53M | $118.78M | $120.45M | $91.43M | 32.2% | -10.5% |
| Service and other revenue | $23.23M | $23.85M | $24.25M | $23.69M | $22.52M | $20.10M | $17.87M | $17.10M | $16.55M | $16.20M | $16.65M | $16.88M | 14.6% | +3.1% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $73.12M | $73.18M | $72.80M | $72.26M | $74.27M | $77.34M | $78.71M | $92.47M | $101.34M | $104.55M | $105.41M | $84.02M | 45.9% | -1.5% |
| Europe, Middle East and Africa | $50.54M | $45.58M | $44.05M | $39.56M | $37.92M | $35.48M | $34.59M | $35.56M | $37.44M | $41.14M | $40.66M | $34.76M | 31.7% | +33.3% |
| Asia-Pacific | $35.62M | $41.27M | $43.16M | $42.77M | $43.92M | $39.54M | $40.71M | $45.11M | $50.09M | $54.74M | $54.45M | $50.73M | 22.4% | -18.9% |
From the segment and revenue-disaggregation notes of Pacific Biosciences Of California's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.